Jae Werndli

525 total citations
16 papers, 396 citations indexed

About

Jae Werndli is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jae Werndli has authored 16 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 11 papers in Oncology and 5 papers in Genetics. Recurrent topics in Jae Werndli's work include Lymphoma Diagnosis and Treatment (12 papers), Viral-associated cancers and disorders (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Jae Werndli is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Viral-associated cancers and disorders (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Jae Werndli collaborates with scholars based in United States and Czechia. Jae Werndli's co-authors include Brad S. Kahl, Natalie S. Callander, KyungMann Kim, Walter Longo, Thomas McFarland, Jules H. Blank, Jens C. Eickhoff, Stephanie Markovina, Shigeki Miyamoto and Jihoon Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Jae Werndli

15 papers receiving 390 citations

Peers

Countries citing papers authored by Jae Werndli

Since Specialization

Citations

This map shows the geographic impact of Jae Werndli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jae Werndli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jae Werndli more than expected).

Fields of papers citing papers by Jae Werndli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jae Werndli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jae Werndli. The network helps show where Jae Werndli may publish in the future.

Co-authorship network of co-authors of Jae Werndli

This figure shows the co-authorship network connecting the top 25 collaborators of Jae Werndli. A scholar is included among the top collaborators of Jae Werndli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jae Werndli. Jae Werndli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Elizabeth Chang, Lakeesha Carmichael, KyungMann Kim, Christopher G. Peterson, David T. Yang, Anne M. Traynor, Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Brad S. Kahl	11
2	Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study 2016 ·Blood ·Julie Chang, Christopher G. Peterson, Lakeesha Carmichael, KyungMann Kim, David T. Yang, Anne M. Traynor, Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Brad S. Kahl	2
3	Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study 2016 ·British Journal of Haematology ·Elizabeth Chang, Thomas C. Havighurst, KyungMann Kim, Jens C. Eickhoff, Anne M. Traynor, (unknown), Lynn M. Volk, Jae Werndli, Ronald S. Go, Matthias Weiss, Jules H. Blank, Brad S. Kahl	8
4	Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study 2012 ·Blood ·Julie Chang, Chong Zhang, KyungMann Kim, Rachel Kirby, Lynn M. Volk, Jae Werndli, Ronald S. Go, Matthias Weiss, Jules H. Blank, Michael A. Thompson, John P. Farnen, Craig E. Cole, (unknown), Michael Volk, (unknown), (unknown), Patrick J. Mansky, Anne M. Traynor, Timothy S. Fenske, Brad S. Kahl	1
5	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network 2011 ·Leukemia & lymphoma ·Vaishalee P. Kenkre, (unknown), Jens C. Eickhoff, Jules H. Blank, Thomas McFarland, Wayne A. Bottner, (unknown), Jae Werndli, Howard H. Bailey, Brad S. Kahl	30
6	VcR‐CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study 2011 ·British Journal of Haematology ·Elizabeth Chang, Christopher G. Peterson, Sangbum Choi, Jens C. Eickhoff, KyungMann Kim, David T. Yang, (unknown), (unknown), Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Brad S. Kahl	43
7	Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study 2010 ·Clinical Lymphoma Myeloma & Leukemia ·Julie Chang, (unknown), (unknown), Jae Werndli, Wayne A. Bottner, (unknown), Federico Augusto Sanchez, Thomas J. Saphner, Walter Longo, Brad S. Kahl	13
8	The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317). 2009 ·Blood ·Natalie S. Callander, Stephanie Markovina, Mark Juckett, Elizabeth M. Wagner, Jill Kolesar, Walter Longo, Eliot C. Williams, KyungMann Kim, Jae Werndli, Shigeki Miyamoto	16
9	Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells 2008 ·Molecular Cancer Research ·Stephanie Markovina, Natalie S. Callander, Shelby L. O’Connor, Jihoon Kim, Jae Werndli, (unknown), Catherine P. Leith, Brad S. Kahl, KyungMann Kim, Shigeki Miyamoto	118
10	Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study 2008 ·Hematological Oncology ·(unknown), (unknown), (unknown), HG Ahuja, (unknown), (unknown), (unknown), Jae Werndli, (unknown), (unknown)	29
11	VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network 2008 ·Blood ·Brad S. Kahl, Julie Chang, Jens C. Eickhoff, (unknown), (unknown), Jae Werndli, (unknown), Thomas McFarland, Michael Volk, Jules H. Blank, Natalie S. Callander, Walter Longo, Christopher G. Peterson	14
12	A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma 2007 ·Journal of Clinical Oncology ·Brad S. Kahl, Christopher G. Peterson, Jules H. Blank, Thomas McFarland, (unknown), Jens C. Eickhoff, Jae Werndli, Natalie S. Callander, T.G. Myers	4
13	Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM). 2007 ·Blood ·(unknown), Stephanie Markovina, Shigeki Miyamoto, Walter Longo, Eliot C. Williams, Thomas McFarland, Jae Werndli, Elisabeth Wagner, Mark Juckett, Natalie S. Callander	13
14	Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network 2006 ·Annals of Oncology ·Brad S. Kahl, Walter Longo, Jens C. Eickhoff, James L. Zehnder, Chris Jones, Jules H. Blank, Thomas McFarland, Wayne A. Bottner, (unknown), Jae Werndli, Howard H. Bailey	82
15	Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study 2005 ·Cancer Investigation ·Brad S. Kahl, Howard H. Bailey, KyungMann Kim, Eileen Smith, (unknown), Jamie Smith, Jae Werndli, (unknown), (unknown), Eliot C. Williams, Walter E. Longo	0
16	Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study 2005 ·Cancer Investigation ·Brad S. Kahl, Howard H. Bailey, KyungMann Kim, Eileen Smith, (unknown), (unknown), Jae Werndli, (unknown), (unknown), Eliot C. Williams, Walter Longo	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact